The tweet was deleted by the author.
But we saved everything 🙂.
CVRx reported a 20 percent increase in total revenue for the first quarter, signaling robust growth compared to the same period last year.
The company also recorded a 22 percent surge in U.S. revenue and announced an expansion in active U.S. implanting centers. CVRx outlined its business outlook for 2026, underscoring its commitment to sustained revenue momentum across its markets.
CVRx has highlighted the Barostim device's impact on heart failure outcomes, with Dr. Savitri Fedson sharing a case of patient improvement in previous reporting. Methodist University Hospital recently completed its first Barostim implant through a collaboration with CVRx. The expansion of implanting centers continues the company's recent efforts to broaden treatment access.